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Abstract
Allergic rhinitis (AR) is usually defined as an inflammatory disease of the nasal mucosa
induced by an interaction of environmental allergens and IgE in sensitized patients. Its
symptoms are sneezing, nasal itching, rhinorrhoea and nasal obstruction. Allergic rhinitis
affects approximately 20- 30% of the population worldwide and its prevalence is increas‐
ing. Isolated AR is rare and it actually has to be considered as a systemic allergic disease,
associated to comorbidities, such as conjunctivitis, chronic middle ear effusions, irregular
sleep, sinusitis, lymphoid hypertrophy with obstructive sleep apnoea. The most relevant
comorbidity is asthma, a heterogeneous disease, usually characterized by chronic airway
inflammation in which many cells and cellular elements play an important role. Bronchial
asthma is characterized by bronchial hyper-reactivity and symptoms may be triggered or
worsened by factors such as viral infections, allergens, tobacco smoke, exercise and stress.
A state of "minimal persistent inflammation" is permanently maintained in the lower res‐
piratory tract of asthmatic individuals. The diagnosis of asthma is based on evidence of
variable airflow limitation tested with spirometry and a positive bronchodilation reversi‐
bility test. Skin prick tests (SPTs) are widely used to demonstrate an immediate IgE-medi‐
ated allergic reaction. They represent a major diagnostic tool in the field of allergy. Skin
prick tests have a high specificity and sensitivity for the diagnosis of inhalant allergens.
Immunotherapy (AIT) for allergic diseases has entered in a new age characterized by the
development of a few innovative therapeutic classes of standardized allergen formula‐
tions registered. Clinical randomized trials have demonstrated the efficacy of AIT in al‐
lergic rhinitis in children and in adults, expressed in terms of reduction of symptom score
and use of rescue medication. The efficacy is confirmed both for subcutaneous (SCIT) and
sublingual (SLIT) immunotherapy in adults and in pediatric patients. The long lasting ef‐
fect of AIT after its discontinuation is an important added value of this therapy. Control‐
led studies are available, where the carry-over effect of AIT is demonstrated for two years
after discontinuance. The capacity to prevent new sensitizations, and to modify the evo‐
lution of the disease from the rhinitis to asthma are two important features of AIT. Aller‐
gen immunotherapy showed preventive capacity and also a carryover effect once
treatment is discontinued.
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1. Introduction
Allergic rhinitis (AR) is an inflammatory disease of the nasal mucosa induced by allergens in
sensitized patients with specific immunoglobulin E (IgE).
Its symptoms include sneezing, nasal itching, rhinorrhoea and nasal obstruction. Epidemio‐
logically, AR represents a health problem for both children and adults on a global basis:
approximately 20–30% of the population worldwide suffer its affects and its prevalence is
increasing.
Genetic and socio-environmental factors may influence the development of AR: the urbani‐
zation processes, high levels of motor engine pollution and western lifestyles are significantly
linked to high incidences of respiratory allergy diseases. Allergic rhinitis is not considered to
be a serious disease but it significantly limits daily life activities, such as school and work
performance – this leads to increased direct social costs (i. e., medical costs, mainly related to
symptomatic medications) and indirect costs due to decreased work performance (AR is in
fact one of the most significant causes of absenteeism from work).
The guidelines ARIA introduced for the first time represented a classification of severity of
two degrees, according to the presence or absence of the effects of rhinitis on general well-
being and quality of life (HRQL) and a classification regarding the duration of symptoms:
“intermittent” and “persistent”.
One component part of the symptoms of AR is nasal obstruction –the most disabling symptom
as it seriously affects quality of life by interfering with normal sleep structures and over time
facilitates the onset of complications such as allergic conjunctivitis, rhino-sinusitis and nasal
polyposis, otitis media, adenoid hypertrophy and orthodontic problems.
The most relevant comorbidity is asthma. Past observations about the link between upper and
lower airway disease has generated a united airway disease (UAD) notion. Around 38% of all
AR patients present asthma symptoms or show a higher frequency of bronchial hyper-
reactivity. In addition, 78% of asthma patients present rhinitis symptoms.
Allergic rhinitis can be considered a risk factor for asthma exacerbation. In asthmatic patients,
AR symptoms induce worsened asthma control, more frequent asthma attacks and admission
to emergency rooms; in addition the use of drugs for asthma significantly increases with the
severity of AR. Diagnosis of asthma is based on evidence of a variable airflow limitation which
is tested via spirometry and a positive bronchodilation reversibility test. Another test used to
diagnose asthma is airways responsiveness: it is necessary in this test to measure how airways
react when they are challenged with a trigger. Airway inflammation may also be tested via
measurement of exhaled nitric oxide concentration. Nitric oxide is physiologically produced
by lungs, but higher than normal levels indicate airways are inflamed, a condition which is
associated with asthma.
The concordance of a typical history of allergic symptoms and the results of proper diagnostic
tests forms the basis for AR diagnosis.
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Skin prick tests (SPTs) are usually considered the standard diagnostic procedure to support
an allergic basis for the patient’s symptoms, to confirm suspected causes of the patient’s
symptoms and/or to identify sensitizing allergens.
The SPT represents the first line approach, to be preferred to in vitro IgE determination due to
its high sensitivity, rapidity of performance, simplicity, ease of use and low cost.
International (EAACI, WAO) and national guidelines (SIAAIC) considered in vitro tests for
allergic diseases as second-level tests, to be used after a SPT, for confirmation or in cases when
an SPT cannot be carried out. Specific IgE for inhalant allergens (dust mites, dermatophagoides
pteronyssinus, dermatophagoides farinae , pollens, latex, molds) and for some food allergens
that can induce respiratory symptoms, are measured to understand trigger agents of allergic
diseases such as conjunctivitis, rhinitis, asthma or professional allergic respiratory diseases.
This assay allows identification, in a quantitative way, of the sensitization towards a complete
allergen and/or a specific allergy molecule. The possibility of performing a deeper analysis
with molecular diagnostics gives important information which is more specific than from an
SPT.
The identification of specific IgE against cross reacting molecules such as Profilins, Bet v1-
PR10, lipid transfer protein and calcium-binding protein, or against “genuine molecules”,
represents an added value and allows distinction between true and false polysensitizations.
Component resolved diagnosis has an important impact on the management of the patient in
terms of the accuracy of the diagnosis, or the decision on therapies like specific immunotherapy
prescription.
Immunotherapy for allergic diseases (AIT) has entered a new age, characterized by the
development of a few innovative therapeutic classes of standardized, registered allergen
formulations. AIT is considered a safe and efficacious treatment for patients with type-1
respiratory allergies. The ability of sublingual immunotherapy (SLIT) to elicit antigen specific
tolerance is linked to the peculiar biology of oral antigen-presenting cells. In the absence of
danger signals, Langerhans cells, myeloid dendritic cells and the macrophages located in oral
tissues or the tonsils are biased towards the induction of Th1 and IL 10 producing CD4+
regulatory T cells.
Clinical randomized trials have demonstrated the efficacy of AIT in AR in children and adults,
expressed in terms of are duction in symptom scores and the use of rescue medication.
2. Allergic rhinitis and its comorbidities
Allergic rhinitis (AR) is usually defined as an inflammatory disease of the nasal mucosa
induced by an interaction of environmental allergens and immunoglobulin E (IgE) in sensi‐
tized patients [1].
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Allergic rhinitis is the most widespread type of non-infectious rhinitis. Its symptoms include
sneezing, nasal itching, rhinorrhoea and nasal obstruction. Ocular signs, such as itching of the
eyes, redness and tearing, occur in a large percentage of patients suffering from AR.
Epidemiologically, AR represents a health problem for both children and adults on a global
basis. Allergic rhinitis affects approximately 20–30% of the population worldwide and its
prevalence is increasing. In Italy it is estimated that 24% of the population suffers of AR (data
2007–2010 GEIRD-LIBRA) [2]. Nevertheless, around one-third of allergic patients have never
visited a physician, an observation which suggests that the actual prevalence of AR may be
underestimated with the condition perhaps being mistreated [3].
Allergic rhinitis is usually categorized as a multi-factorial disease and many hypothesis
hypotheses have been suggested to explain its increasing occurrence.
As in case of asthma, genetic factors may influence the development of AR; these diseases
reveal strong familial and intra-individual clustering, implying an overlapping disease
aetiology.
A socio-environmental hypothesis is based on several studies, demonstrating that the urban‐
ization process, high levels of motor engine pollution and western lifestyles are significantly
linked to the high incidence of respiratory allergy diseases, found to prevail among inhabitants
of metropolitan areas over rural areas [4].
Allergic rhinitis is not considered a serious disease and although it is certainly not life
threatening it does significantly limit daily activities such as an individual’s performance at
school or work, which leads to increased direct social costs (i. e., medical costs, mainly related
to symptomatic medications) and indirect costs due to a decrease in workforce performance
(AR is in fact one of the most significant causes of absenteeism).
The guidelines ARIA introduced had for the first time a classification of severity of two degrees,
according to the presence or absence of the effects of rhinitis on general well-being and on the
quality of life (health-related quality of life, HRQL).
By means of a validated questionnaire, it has been possible to demonstrate that AR has a real
and measurable impact on HRQL, considered more important than more serious, chronic
diseases, such as diabetes mellitus. For a patient with AR, important limitations coexist, due
directly to rhinitis symptoms and indirectly to chronic use of drugs –both can impact social
life: e. g., sleep disorders leading to daytime sleepiness and increased accidents, difficulty in
concentrating, headaches, mood changes, depression, irritability and fatigue. When consid‐
ered altogether, these conditions can heavily weigh on a person’s social and professional life
[5].
As part of the symptoms of AR, nasal obstruction is the most disabling as it seriously affects
quality of life by interfering with normal sleep patterns. It also facilitates the onset of compli‐
cations such as rhino-sinusitis and nasal polyposis.
Allergic Rhinitis classification is based on both duration and chronicity as well as on the
grading of severity (mild or moderate–severe) of symptoms. It also takes into account the
impact of the disease on daily activities, such as work/school performance and impaired sleep.
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Regarding duration of symptoms, AR is defined “intermittent” when it occurs less than 4 days
per week or less than 4 consecutive weeks per year. Vice versa, “persistent” AR occurs when
symptoms are present more than 4 days per week and more than 4 consecutive weeks per year.
Isolated AR is rare and it actually has to be considered as a systemic allergic disease, associated
to comorbidities, such as conjunctivitis, chronic middle ear effusions, irregular sleep, sinusitis,
lymphoid hypertrophy with obstructive sleep apnoea. However, the most relevant comorbid‐
ity is asthma. Past observations about the link between upper and lower airways disease has
generated the notion of united airway disease (UAD) [6].
The relationship between the two compartments is clinical, epidemiological, functional and
immunological. Subsequently, the official standpoint is that rhinitis is both allergic and non-
allergic, and is acknowledged as a risk factor for asthma.
Recent surveys show that around 38% of all AR patients present asthma symptoms too. On
the other hand, 78% of asthma patients present rhinitis symptoms.
This finding is based not only on epidemiological data but also on physiological evidence. In
fact, patients with AR (even without asthma) show a higher frequency of bronchial hyper-
reactivity. This could be linked to the duration of AR and the number of sensitizations of
patients.
Furthermore, AR can be considered as risk factor for asthma exacerbation. In asthmatic
patients, AR symptoms induce worsened asthma control, more frequent asthma attacks and
admission to emergency rooms. In addition, the use of drugs for asthma significantly increase
with the severity of AR.
Other comorbid disorders and links to AR, are:
a. Allergic conjunctivitis, resulting in conjunctival injection chemosis, itchy eyes and
tearing. These symptoms have been observed in more than 75% of patients with AR caused
by pollen. Moreover, patients sensitized to pollen report ocular symptoms more frequent‐
ly than patients sensitized to house dust mites [7].
b. AR patients compared with non-allergic subjects are more frequently affected by
rhinosinusitis. Infections of the ear and of the nasal and paranasal sinuses are conditions
secondary to the obstruction of the Eustachian tube as a consequence of local inflamma‐
tory infiltrate [8]. Patients with AR, particularly those sensitized to house dust mites,
rarely develop nasal polyps [9]. Some studies show that around 21% of AR patients are
affected by otitis media. In the case of AR in children, the incidence of otitis media is twice
as large when compared to non-allergic children [10].
c. It has been reported that among children with AR, particularly if sensitized to dust mites,
adenoid hypertrophy (AH) occurs significantly more frequently than in children with
other allergic diseases (asthma/atopic dermatitis) or without allergies. Sleep and quality
of life: nasal obstruction resulting from rhinitis causes sleep disorders, fatigue and
tiredness during the day, as well asloss of smell and taste [11]. Chronic nasal obstruction
in children can cause excessive breathing through the mouth which leads to orthodontic
problems such as an excessive stretching of the face and malocclusion.
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The concordance of a typical history of allergic symptoms and the results of properdiagnostic
tests formsthe basis of AR diagnosis.
Skin prick tests (SPTs) are usually considered the standard diagnostic procedure to support
an allergic basis for the patient’s symptoms, to confirm suspected causes of the patient’s
symptoms and/or to identify sensitizing allergens.
The reasons for preference of the SPT as a first line approach, over in vitro IgE determination
are the following: high sensitivity, rapidity of performance, simplicity, ease of use and low
cost.
Nonetheless, particular situations (extensive skin disease, skin test suppressive therapy, such
as antihistamines that cannot be discontinued, or uncooperative patients) are indications for
using serum specific IgE determination by immunoassays.
In some cases of rhinitis further study is useful via fibre optic nasal endoscopy, such as for a
typical symptoms or physical findings, complications, other suspected conditions or when
symptoms apparently do not respond to therapy. For suspected complications or comorbidi‐
ties such as nasal polyposis with sinusitis, a computed tomography (CT) scan may be useful.
Before prescribing immunotherapy it is useful to study nasal cellularity via nasal cytology [12].
Cytological findings can in fact support the allergic pathogenesis of rinithis (neutrophil
infiltration for mite allergy, eosinophilic infiltrate in the case of hay fever) or might indicate
non-allergic rhinitis [13].
3. Asthma
Asthma is a heterogeneous disease, usually characterized by chronic airway inflammation in
which many cells and cellular elements play an important role.
Chronic inflammation causes an associated increase in airway hyper-responsiveness leading
to recurrent episodes of wheezing, breathlessness, chest tightness and coughing, particularly
at night or in the early hours of the morning. Generally, these episodes are accompanied by
widespread but variable airflow obstruction that is often reversible, either spontaneously or
following therapy.
The pathogenesis of these alterations involves many mechanisms, in particular inflammatory
cell infiltration, mediator release and airway remodelling.
As reported in the definition, bronchial asthma is characterized by bronchial hyper-reactivity,
and its symptoms may be triggered, or worsened, by factors such as viral infections, allergens,
tobacco smoke, exercise and stress. A state of "minimal persistent inflammation" is perma‐
nently maintained in the lower respiratory tract of asthmatic individuals. The intensity of
clinical symptoms varies in relation to the actual size of the bronchial obstruction and to the
degree of its subjective perception by the patient [14].
The probability that respiratory disease is really asthma becomes lower if the patient has:
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• An isolated cough with no other respiratory symptoms. Chronic production of sputum.
Shortness of breath associated with dizziness, light-headedness or peripheral tingling. Chest
pain. Exercise-induced dyspnoea with noisy inspiration (stridor).
The diagnosis must be done preferably before starting treatment because it is often more
difficult to confirm the diagnosis afterwards.
It is increasingly clear that bronchial asthma is not a single disease but a complex set of
overlapping syndromes; for classification purposes it is necessary to take into account the
phenotype of the disease resulting from a given set of genetic and environmental interactions.
In a recent review a classification has been proposed based on phenotypes of asthma which
takes into account both clinical and physiological triggers as well as the cell types involved in
inflammation.
From the clinical and physiological point of view it is necessary to classify asthma according
to its severity; in order to define severity several parameters are considered: for instance, the
frequency of exacerbations and age of onset correlate with a more favorable prognosis and
improved lung function in the case of early-onset, typically allergic asthma; in contrast,
resistance to drug treatment(especially neutrophilic asthma) and its possible association with
chronic restriction is mainly observed in non-allergic patients.
As far as triggering factors are concerned, bronchial asthma should be further divided into
allergic asthma, often associated with rhinitis and conjunctivitis but with a favorable progno‐
sis; exercise-induced asthma; occupational asthma (about15% of asthma in adults); aspirin
sensitive asthma (with eosinophilic inflammation and frequent association with nasal poly‐
posis and sinusitis) and premenstrual asthma [15].
Finally, asthma should be characterized according to the specific cellularity responsible for
inflammation in eosinophilic or neutrophilic. It is increasingly clear that the correct identifi‐
cation of phenotype of asthma is essential to set a targeted therapy and to obtain good control
of symptoms and improve the quality of life of patients [16]. The classification of severity of
asthma is assessed retrospectively from the level of treatment required to control symptoms
and exacerbations:
• Mild asthma: well controlled with as needed relief medication alone or with a low dose of
inhaled corticosteroids (ICS), leukotriene receptor antagonist or cromones.
• Moderate asthma: well controlled with a low dose of ICS/long-acting beta agonist (LABA).
• Severe asthma: controlled with high dose ICS/LABA or asthma that remains uncontrolled
despite this treatment. In the diagnosis of severe asthma it is important to exclude common
causes of uncontrolled asthma such as poor inhaler technique, poor medication adherence,
incorrect diagnosis of asthma, comorbidities (rhinosinusitis, gastroesophageal reflux,
obesity, obstructive sleep apnoea).
Asthma can be effectively treated and when asthma is well-controlled, patients can avoid
troublesome symptoms during the day and night, need little or no relief medication, have
productive, physically active lives, normal lung function and avoid serious exacerbations.
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The diagnosis of asthma is based on evidence of variable airflow limitation tested with
spirometry and a positive bronchodilation reversibility test [17].
The spirometry allows to two main measurements: the volume of air that the patient can exhale
in the first second of exhalation (the forced expiratory volume in one second, or FEV1] and the
total amount of air that the patient blows out (the forced vital capacity or FVC). These readings
are compared against the average measurements for people of the same age, sex and height,
and immediately indicate if airways are obstructed or not. The most important spirometric
value is the FVC. To measure FVC, the patient inhales maximally, and then exhales as rapidly
and as completely as possible. Normal lungs generally can empty more than 80%of their
volume in 6 seconds or less. The forced expiratory volume in one second (FEV1] is the volume
of air exhaled in the first second of the FVC maneuver. The FEV1/FVC ratio is expressed as a
percentage and is known as the Tiffeneau Index. A reduced value of FEV1 and of absolute
FEV1/FVC ratio indicates an obstructive ventilatory pattern. In this case, a bronchodilator
challenge test is recommended to detect patients with reversible airway obstruction. This is
known as “reversibility testing”, and it can be useful in distinguishing asthma from other lung
pathological conditions, such as chronic obstructive pulmonary disease (COPD).
Another test used to diagnose asthma is airway responsiveness. When the diagnosis is not
possible from the above described test it is necessary to measure how airways react when they
are challenged with a trigger. The test involves inhaling progressively increasing amounts of
a medication (e. g., metacholine, histamine) at regular intervals, and taking FEV1 measure‐
ments to see if they fall below a certain threshold (typically 80% of baseline values). In some
cases, exercise may be used as a trigger.
Testing airway inflammation may also be useful. This can be done by measuring the exhaled
nitric oxide concentration. Nitric oxide is physiologically produced by the lungs, but higher
than normal levels indicate airways are inflamed, a condition which is associated with asthma
[18].
4. Allergy diagnostics in vivo: when, what, who?
The SPT is widely used to demonstrate an immediate IgE-mediated allergic reaction. These
tests represent a major diagnostic tool in the field of allergy. Skin prick tests have a high
specificity and sensitivity for the diagnosis of inhalant allergens.
Their simplicity, rapidity of performance, low cost, and high sensitivity explain their key
position in the diagnosis of allergies. If properly performed, they yield useful evidence for the
diagnosis of a specific allergy. In respiratory allergies skin tests represent the first diagnostic
method used in patients with a suggestive clinical history of allergic rhinitis, conjunctivitis
and/or asthma. They can be used from infancy to old age [19].
Usually, skin tests are performed on one or both forearms, depending on the age and size of
the patient. SPTs can be performed and interpreted in infants; usually the size of the lower arm
limits the number of allergens that can be tested. Prick testing involves introducing a needle
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into the upper layers of the skin and releasing a drop of allergen extract after gently lifting the
epidermis. The release of preformed histamine from mast cells causes increased vascular
permeability via smooth muscle contraction and development of a wheal; inflammatory
mediators initiate a neural reflex causing vasodilatation, leading to erythema (the flare). The
distance between two prick tests should be 2 cm to avoid cross-contamination [20]. It is
important to avoid bleeding of the skin. Negative (saline) and positive (e. g., 9% histamine
hydrochloride solution) controls are required in SPTs to make any interpretation possible. The
positive control should optimally show a wheal diameter of ‡3 mm [21].
Skin tests are regarded positive if the mean wheal diameter is ≥3 mm. Very large reactions are
not necessarily associated with a more severe disease. Skin test results may be negative even
if patients are allergic. If a skin test is positive, one will have to distinguish reactions which are
clinically relevant from those which are not. History and/or challenge tests help to clarify the
relevance of a sensitization. Usually, a clinically irrelevant sensitization does not lead to
practical consequences.
Drugs can suppress skin tests, therefore, it is always necessary to ask patients about the
medication they have taken in the preceding days. This is particularly the case for oral H1-
antihistamines [22], but I also the case for anxiolytics –not however for antidepressants [23].
Topical skin corticosteroids may also alter skin reactivity. The inhibitory effect of H1-antihist‐
amines lasts about 2–7 days while the inhibitory effect of topical steroids lasts up to 7 days.
False-positive skin tests may result from dermographism, ‘irritant’ reactions or a non-specific
enhancement from a nearby strong reaction. Contamination of the needle by another allergen
extract may also induce false-positive results. To overcome this problem, it is recommended
that needles or puncture devices be changed between each test.
False-negative skin tests can be caused by poor potency of extracts [24], drugs modulating the
allergic reaction, diseases attenuating the skin’s response, weak punctures or a limited local
production of allergen-specific IgE– only in the nose [25] or eyes [26].
Inhalant allergens to be tested should be chosen after considering various factors: the spread
environment, the homologies between the various pollen and lifestyle habits. The Global
Allergy and Asthma European Network suggested a panel of allergens to be tested in all
patients in Europe: Pollen (Birch, Cypress, Grass, Mugwort, Olive, Parietaria officinalis,
Ragweed), house dust mites, animals (dog and cat) and moulds (Alternaria, Cladosporium).
The SPT is usually considered to be a safe procedure, but recently there have been occasional
reports of generalized allergic reactions or vasovagal reactions [27]. Based on the literature, the
occurrence of systemic reactions with inhalant allergens has diminished over the last 30years.
In general, the risk of systemic reactions is lower with SPTs than with intradermal testing. Some
patients (those with histories of previous anaphylactic reactions, small children, pregnant
women,  uncontrolled  asthmatic  sand those  with  a  high  degree  of  reactivity)  should  be
considered at higher risk of systemic/anaphylactic reactions. Based on the literature, the risk of
fatality due to an SPT is extremely remote, and severe/anaphylactic reactions are rare. Never‐
theless, this risk cannot be completely excluded, especially in highly susceptible subjects.
Physicians who perform SPTs should be aware of this and apply simple precautionary rules [28].
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5. Allergy diagnostics in vitro: few appropriate allergens
Specific IgE can be detected either in vivo by SPTs or in vitro by specific IgE assay: both methods
usually employ whole extracts from allergenic sources which contain a mixture of allergenic
and non-allergenic proteins [29] –the IgE response is specifically directed towards some
molecules [30]. Specific IgE for inhalant allergens (dust mites, dermatophagoides pteronyssi‐
nus, dermatophagoides farinae, pollens, latex, molds) and for some food allergens that can
induce respiratory symptoms (serum albumin, wheat flour, casein, fish parvalbumin, vegeta‐
bles as Lipid Transfer Protein, lysozyme, etc.) are measured to understand the trigger agents
of allergic diseases such as conjunctivitis, rhinitis, asthma or professional allergic respiratory
diseases.
International (EAACI European Allergy Asthma Clinical immunology, WAO World Allergy
Organization) and National Guidelines (SIAAIC Società italiana Asma Allergia Immunologia
Clinica) considered in vitro tests for allergic diseases as a second-level test, to be used after the
SPT, for confirmation or in the case where the SPT cannot be carried out because the patient
takes antihistamine drug so r shows atopic dermatitis, etc.
Measurement of in vitro specific IgE (sIgE) is an important tool.
It allows the identification, in a quantitative way, of the sensitization towards a complete
allergen and/or a specific allergy molecule. The possibility to perform a deeper analysis with
molecular diagnostics gives important information, more specific than that gained from the
SPT. Specific IgE is usually measured for common allergens: dermatophagoides, grass, trees,
cypress, pellitory, ragweed, plantagolanceolata, olive pollen, alternaria, dog and cat dander
and cladosporium herbarum with particular concern to botanicals.
Extractive preparations used for SPTs usually contain cross-reactive components which are
highly conserved across widely different allergen sources [31]. This may complicate the
interpretation of the diagnostic results, especially in polysensitized subjects. The introduction
of highly purified natural and recombinant single allergenic molecules represents an impor‐
tant improvement in the diagnosis of IgE sensitizations and cross reactivities.
6. Component resolve diagnostics
The identification of a specific IgE against cross-reacting molecules such as Profilins, Bet v1-
PR10, lipid transfer protein, calcium-binding protein or against “genuine molecules”, repre‐
sents an added value and allows the distinction between true and false polysensitizations. A
true polysensitization occurs when specific IgE is present against genuine components of
different allergenic sources. The genuine molecules for grass sensitization are: Phl p1, usually
the first allergen of grass induces IgE and Phl p 5; Bet v 1, is the genuine molecule of birch, Par
j2 of Pellitory, Pla l 1 of Plantago l, Amb a 1 of ragweed, Fe d1 of cat, Der p 1 and Der p 2 of
Dermathophagoides are the genuine molecules of dust mites. False polysensitizations are due
to the presence of panallergens like profilin or calcium-binding proteins causing SPT positive
results [32].
Primary Care in Practice - Integration is Needed152
Component resolved diagnosis (CRD) has an important impact on the management of the
patient in terms of the accuracy of the diagnosis, or decision on therapy (like specific immu‐
notherapy prescription). Recent studies [33] demonstrated that CRD use in the diagnostic
pathway implies a change in the decision regarding treatment in more than 50% of patients
compared to diagnosis based only on clinical history and skin test results [34].
An in vitro test is useful in these cases:
• Positive SPT is in agreement with clinical history –in this case in vitro tests add information [35]
and allows: Detect of patients with sensitization to genuine molecules that cause allergic
diseases [2]. Distinction among patients with positive prick tests for more than one allergen,
about70% of allergic patients have a polysensitization due to sensitization to pan-allergens
[36, 37]. Evaluate in childhood of the “spreading” of sensitization towards each grass
molecule and has prognostic information about the evolution of the disease: a correlation
between phenotypes of sensitization and illness severity [38, 39, 40]. Choice of better
therapies: if only clinical history and prick tests are used, without the support of CRD results,
the choice of the therapy is incorrect in more than 50% of the cases, with an important cost
increase [41, 42, 43]. Identification of the ideal patient for immunotherapy, represented by
the patients with sensitization towards genuine molecules [44, 45] with high possibilities of
improving symptoms and increasing safety during administration. Improvement to quality
of life of allergic patients via the correct diagnosis [32]. Detection of patients with sensiti‐
zation to pan-allergens such as profilin or calcium-binding protein. This can induce cross-
reactivity with foods and pollens. Additionally, symptoms are shown for a long period of
time if pollen grains are not detected in the air: the profilin, a molecule from grass, trees,
ragweed pollen is able to induce nasal and bronchial inflammation for a long time period
[34]. Management of the risk of anaphylaxis for allergic latex patients: it is important to
detect IgE for latex molecules inducing anaphylaxis like Hev b 1, Hev b 3, Hev b 5, Hevb 6,
to predict the risk of anaphylaxis; patients with only IgE for Hev b8 are not able to develop
anaphylaxis because Hev b8 is not present in the surgery devices.
• Negative prick tests and clinical history suitable for allergies: when there is not agreement between
prick test results and clinical history. Sometimes prick tests are less sensitivity than in vitro tests
because the extract used for prick tests could miss some important allergenic molecules. In
vitro tests can identify IgE towards particular molecules that induce allergic professional
reactions: serum albumin, lipid transfer protein, lysozyme intake like preserves in some
drugs, molecular allergens of Aspergillus like Asp f 4, Asp f6, Asp f 3 markers of Broncho‐
polmonar Aspergillosy or molecular allergens of Alternaria like the Alt a 1 marker of asthma
[46, 47].
6.1. Allergen-specific immunotherapy can modify the natural history of allergies: The
eligible patient
Immunotherapy for allergic diseases has entered a new age characterized by the development
of a few innovative therapeutic classes of standardized, registered allergen formulations,
which have been assigned marketing authorization codes (in Italy: AIC, Autorizzazioneall’Im‐
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missione in Commercio) as bona fide pharmaceutical specialties, having been supported by
large and robust, randomized controlled clinical trials (RCT) [48].
The European Academy of Allergy Clinical Immunology EAACI and the American Academy
of Allergic Asthma and Immunology (AAAI) has recently proposed the term “allergen
immunotherapy” (AIT) to indicate the treatment of an allergic disease by a drug containing a
given allergen.
To date, AIT products available on the market can be administered as sublingual immuno‐
therapy (SLIT), but in principle subcutaneous immunotherapy (SCIT) products could be
registered as well. AIT is considered a safe and efficacious treatment for patients with type-1
respiratory allergies [49, 1]. The ability of SLIT to elicit antigen-specific tolerance is linked to
the peculiar biology of oral antigen-presenting cells. In the absence of danger signals, Langer‐
hans cells, myeloid dendritic cells, macrophages located in oral tissues or tonsils are biased
towards the inductions of Th 1 and IL 10 producing CD4+ regulatory T cells. This supports the
induction of tolerance rather than an effector immune response generating inflammation.
Sublingual administration does not lead to any detectable systemic exposure of intact allergens
nor to the induction of new IgE sensitizations. Furthermore, due to the limited numbers of
mast cells located in submucosal areas, SLIT has a very favorable safety profile, being adverse
in its reaction locally and, only rarely systemically. The induction of CD4+ regulatory T cells
and blocking anti-inflammatory IgGs or IgAs is considered important for tolerance induction
after SLIT [50]. The clinical efficacy of AIT is supported by numerous clinical trials and meta-
analyses [51].
6.1.1. Eligible patient for AIT
To identify the right patient to benefit from AIT the following criteria should be considered.
A) Proper diagnosis (IgE-mediated respiratory diseases).
B) Symptoms
• Rhinocongiuntivitis (rhinitis should be mild–severe persistent according to ARIA).
• Persistent symptoms for subjects responding poorly to medication. Interference with quality
of life.
• Worsening of quality of life (sleep, social, working and school activities).
• Poor compliance to pharmacological therapy.
• Lack of comorbilities.
6.1.2. Clinical efficacy and disease-modifying effect
Clinical randomized trials have demonstrated the efficacy of AIT in AR in children and adults,
expressed in terms of are duction of symptom score and use of rescue medication. The efficacy
is confirmed both for subcutaneous (SCIT) and sublingual (SLIT) immunotherapy in adults
and pediatric patients. AIT efficacy has been demonstrated with these allergenes: alternaria,
grass, birch, pellitory, ragweed and Dermatophagoides.
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In childhood SLIT is preferred to SCIT for patient compliance and safety.
The choice of SLIT or SCIT depends on several factors, including clinical conditions and risk–
benefit evaluation. The long-lasting effect of AIT after its discontinuation is an important
added value of this therapy as compared to pharmacological therapy. Controlled studies are
available, where the carry-over effect of AIT is demonstrated, including the capacity to
decrease symptom scores and rescue medication for two years after discontinuance. Previ‐
ously, SLIT with non-registered products had been reported to maintain a favorable effect on
patient respiratory allergies up to 12 years after discontinuation.
The capacity to prevent new sensitizations and to modify the evolution of the disease from
rhinitis to asthma are two important features of AIT [52]. A trial which will formally evaluate
the prevention of asthma with grass-based AIT is ongoing [53].
As part of acorrect allergic evaluation at baseline, the “asthma control test” (ACT), the “visual
analog scale” (VAS) of symptoms, the results of spirometry and records of drug consumption
should be completed before beginning AIT.
AIT is usually continued for 3–5 years. Patients undergoing this treatment should be controlled
at least yearly and at the end of the treatment re-evaluated via ACT, VAS, spirometry and drug
consumption.
Recent multicenter randomized double-blind studies with AIT in tablet form (registered drugs
with AIC) demonstrated changes in the natural history of the disease.
The primary endpoint of this randomized controlled clinical study was to evaluate the efficacy
of 75. 000 SQ grass tablets in patients with rhinoconjunctivitis to grass-based pollen. Major
end-points were the score of rhinoconjunctivitis symptoms and symptomatic drug usage. The
observation was extended not only to the 3 years of treatment but also to the 2 years of follow
-up without therapy, in order to document the “disease modifying effect”, according to the
EMA’s European Medicines Agency definition.
A total of 634 patients were randomized (1:1) to receive the tablet or placebo once a day.
The subjects had to receive the drug 4–8 months before the start of the grass pollen season.
The subjects in the active arm of this study had a symptoms score and drug usage of 31% and
21% lower than placebo, respectively.
If we also consider the weighted average of the combined score of symptoms and drug efficacy
in the long term it is even more evident. The effect of the weighted mean score of symptoms
and medications was 33%, and in each study year statistically significant results were observed.
Some studies also included patients with mild and/or moderate asthma. In this case the
combined weighted score for the symptoms of asthma was reduced by 39% compared to the
placebo over the entire pollen season and 44% when taking into account only the peak of the
pollen season. Importantly, a carry-over effect was observed both in the first and second year
after the discontinuation of a 3-year treatment.
The treatment at the end of the fifth year (3 years of treatment and 2 years of follow-up without
treatment) resulted in a statistically significant and clinically relevant 25% reduction (p = 0.
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004) in the score of rhinoconjunctivitis symptoms, associated with a reduced usage of symp‐
tomatic drugs. In addition, the combined score of symptoms and medication showed a
statistically significant reduction (-33%) on average for the 5 pollen seasons.
The efficacy of treatment was similar in monosensitized and polisensitized patients.
When considered together, these data confirm that AIT is capable of modifying the natural
history of allergic with a carry-over effect which, being persistent for at least 2years after AIT
discontinuation, can be considered “disease modifying” according to an EMA classification
document [54].
6.1.3. Polisensitized patients
Epidemiological studies and clinical trials have shown that the percentage of polisensitization
ranges from 20% to 90% with great variability depending on populations.
Polisensitization may also be associated with different clinical pictures with respect to
monosensitized patients, especially those with a more impaired quality of life and more severe
symptoms. In addition allergic children seem to display a higher frequency of sensitizations
than their parents, especially in families with polisensitization. In addition, a small proportion
of patients remain monosensitized during their whole lives. A functional defect of T-regulatory
cells may explain the tendency to develop polisensitization. Children with persistent mono‐
sensitization produce higher amounts of Interleukin 10 and interferon gamma than children
who develop polisensitization. This observation might envisage different immunologic
phenotypes for monosensitizedand polisensitized patients [55]. While in North America AIT
is composed of a mix of allergens, in Europe clinicians prefer to identify the most important
allergen causing symptoms to choose AIT.
A series of real life multicentre observational studies named POLISMAIL (Polysensitization
Impact on Immunotherapy) were conducted to elucidate the clinical relevance of polisensiti‐
zation and were conducted in 11 allergy centers in Italy.
The POLISMAIL studies are based around several issues: polisensitization usually starts from
childhood – polisensitization progresses with age for up to 80% of allergic adults – polisensi‐
tizationmay depend on a T-regulatory cell defect – polisensitization may significantly affect
quality of life – polisensitizationmay be associated with more severe symptoms– polisensiti‐
zation may discourage immunotherapy prescription.
The POLISMAIL studies indicated that polisensitization should not constitute an obstacle to
AIT prescription. Only the clinically relevant allergens, such as the sensitizing allergen which
is capable of inducing symptoms when inhaled, were chosen for AIT 56Some cases demon‐
strate true polisensitizations, other cases are sensitizations for pan allergens like profilin or
calcium-binding proteins. Component resolve diagnosis (with either recombinant or purified
allergens for prick tests or IgE in serum dosage) is a tool to improve the accurate identification
of the sensitization allergens [57, 58]. A positive skin test could be a sensitization to a major
allergen or simply be a result of a cross-reacting response to a panallergen like profilin Bet v
2 or Phl p 12, present with small conformational changes in both species of pollen. The
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demonstration of sensitization for genuine allergenic components and/or pan allergenic
components can modify vaccine strategies [59].
6.1.4. AIT and quality of life
The aim of this position paper (the GA [2] LEN taskforce on patient reported outcomes (PROs)
and health-related quality of life (HRQL)) is to define PROs and their meaning in asthma and
rhinitis treatment, explore the available tools to provide criteria for a proper choice, identify
patient-related factors which could influence PRO assessment, define specific recommenda‐
tions for assessment, analysis and results spreading and underline unexplored areas and
unmet needs. PROs assessment is gaining increasing importance, and it must be performed
with a rigorous methodological procedure using validated tools. This approach enables a
better understanding of patient-related factors influencing clinical trials and real-life manage‐
ment outcomes, identify patients subgroups that can benefit from specific treatment and
management plans and tailor treatment to address PROs (not only physician-defined targets)
to improve allergic asthma and rhinitis management and therapy. Allergic diseases can deeply
interfere with patients’ HRQL with detrimental effects to life being physical, psychological
and social. Allergic rhinitis and asthma cause substantial social and economic burdens. School
and work performance, including school and work absences, daily activity and quality of life
are significantly impaired in both children and adults with respiratory allergies.
In order to measure if allergy disease modifies quality of life [60] many validated question‐
naires are available. Most of them are specifically developed for AR, asthma and the evaluation
of patients in AIT. HRQL has become an increasingly important aspect of outcome evaluation
in healthcare research, providing a more comprehensive approach to patients, proving that
nowadays we cannot renounce this tool [61].
International guidelines consider quality of life and other PROs an important primary outcome
of clinical trials in order to evaluate the efficacy of AIT in allergic respiratory diseases (“Guide‐
line on the clinical development of products for specific immunotherapy for the treatment of
allergic diseases” 20 November 2008). Some variables could interfere with the results of PROs:
age, stress, depression, coping, alessitimia. Clinical randomized trials show that AIT (SCIT and
SLIT) improves quality of life and HRQL significantly [62, 63]).
6.1.5. Safety and tolerability
Clinical trials demonstrated that SLIT is generally safe and well tolerated in a real world setting.
Usually adverse events are mild with rare and few severe reactions. Adverse reactions occur
frequently during the first month of initiation or at the first administration: this confirms the
importance of the first uptake being in the physician‘s office. Most of the patients show mild
to moderate adverse reactions at the beginning of the treatment, however, the side effects tend
to disappear after a few minutes. No fatal or near-fatal adverse reactions have been noticed [64]
6.1.6. AIT cost- effectiveness
The social costs of AR are very relevant and are estimated to be 4–6 billion dollars/year in the
United States with average annual costs of 1089 euros per child and 1549 euros per adult in
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Europe. The cost is higher if allergic asthma is included. Allergen immunotherapy showed a
preventive capacity and also a carry-over effect once the treatment is discontinued.
International literature on the cost-effectiveness of immunotherapy for respiratory allergies
included studies conducted based on an economic evaluation of AIT or allergic rhinoconjunc‐
tivitis, AR, asthma and rhinitis in combination with asthma. The evidence appears to support
the cost-effectiveness of immunotherapy compared with pharmacotherapy for allergic
rhinoconjunctivitis, and subcutaneous immunotherapy compared with pharmacotherapy for
AR and asthma [65, 66].
The cost-effectiveness of immunotherapy depends on the duration of the clinical benefit of
AIT following treatment discontinuance and on the break-even point of cumulative costs
between immunotherapy and pharmacotherapy. This retrospective, and partly cross-section‐
al, study shows that high-dose sublingual immunotherapy may be effective in reducing the
burden of disease as measured by the number of exacerbations need for medical visits and
school–nursery time losses, with a considerable reduction of annual management costs. Also
when considering only direct medical costs, the reduction is clear and appreciable when
considering the whole population, as well as in the allergen type sub-samples and in the case-
control sub-analysis of allergic asthmatic patients [67]. Patients with newly diagnosed AR
initiating AIT incurred significantly in a lower healthcare costs than matched control subjects
beginning 3 months after AIT initiation and continuing throughout the 18 month follow-up
period. The significant cost benefits achieved by children with AR diagnoses who initiated
AIT were also observed for adults with AR [68].
A prospective study demonstrated that SCIT was cost effectiveness after 6years of follow-up,
in particular 3years after the drop of AIT [69]. The comparison of the cost of AIT and drug
treatment must be discussed regarding the few available studies conducted in Germany and
in the United states in the 1990s. Buchner reported in a retrospective, 10-year study that the
direct and indirect costs in patients with AR and asthma were reduced by 54% in subjects
treated with AIT compared with those treated with symptomatic drugs. Fisher estimated that
the use of AIT could save respectively DM500 (610 dollars) and DM 1000 (1220 dollars) per
year in subjects with AR and asthma. A recently retrospective study examined the economic
effect of 3 years of AIT and a follow-up of 10 years: and found that the advantage ofdrug
therapy started after 6 years.
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